Viewing Study NCT01058512


Ignite Creation Date: 2025-12-26 @ 11:07 AM
Ignite Modification Date: 2026-02-26 @ 12:20 AM
Study NCT ID: NCT01058512
Status: COMPLETED
Last Update Posted: 2022-07-25
First Post: 2010-01-26
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
Sponsor: Cellectar Biosciences, Inc.
Organization:

Study Overview

Official Title: A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin
Status: COMPLETED
Status Verified Date: 2022-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: NOV-205
Brief Summary: The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with hepatitis C.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: